What is HealthEquity's R&D?

HealthEquity (HQY) reported R&D of $67.77M in Q1 2026.

How has HealthEquity's R&D changed year-over-year?

HealthEquity's R&D increased by 10.3% year-over-year, from $61.44M to $67.77M.

What is the long-term trend for HealthEquity's R&D?

Over 4 years (2022 to 2026), HealthEquity's R&D has grown at a 13.6% compound annual growth rate (CAGR), from $157.36M to $262.51M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

HealthEquity HQY R&D

R&D at other companies

VicorVICR

$22.29M+15.0%

PTCPTC

$124.13M+11.8%

HasbroHAS

$78M-3.1%

Tempus AI, Inc.TEM

$48.24M+34.5%

AccentureACN

$204.33M-29.0%

Ford Motor CompanyF

$2.35B+17.5%

Other financials

Income statement

See full

Revenue$354.6M+7.2%

Gross profit$256.3M+14.3%

Operating income$103.0M+23.9%

Net income$69.4M+28.8%

EPS (diluted)$0.82+34.4%

Balance sheet

See full

Cash & equivalents$265.4M-7.8%

Total debt$984.7M-11.0%

Total equity$2.0B-3.6%

Total assets$3.3B-3.2%

Cash flow

See full

Operating cash flow$97.5M+50.6%

CapEx$362.0K+321%

Free cash flow$97.2M+50.3%

Valuation

See full

Market cap$7.12B-6.7%

Enterprise value$7.84B-7.2%

P/E30.9×-31.8×

P/S5.3×-0.8×

Profitability

See full

Gross margin70.7%+5.2pp

Operating margin25.6%+9.2pp

Net margin17.3%+7.5pp

FCF margin36.5%+9.3pp

Returns & leverage

See full

Return on equity11.1%+5.3pp

Debt / equity0.5×0.0×

Current ratio3.4×-0.6×

Where this comes from

Reported directly by HealthEquity in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: HealthEquity’s 10-Q, filed May 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about HealthEquity's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is HealthEquity's R&D?: HealthEquity (HQY) reported R&D of $67.77M in Q1 2026.
How has HealthEquity's R&D changed year-over-year?: HealthEquity's R&D increased by 10.3% year-over-year, from $61.44M to $67.77M.
What is the long-term trend for HealthEquity's R&D?: Over 4 years (2022 to 2026), HealthEquity's R&D has grown at a 13.6% compound annual growth rate (CAGR), from $157.36M to $262.51M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.